1 / 26

FP6 Thematic Priority 1: Life Sciences, Genomics, and Biotechnology for Health

FP6 Thematic Priority 1: Life Sciences, Genomics, and Biotechnology for Health Dr. Neil T. M. Hamilton Executive Director. Synopsis. Areas of focus in this Thematic Priority What’s left in FP6 Why you should be involved How to get involved http://www.cordis.lu/fp6/lifescihealth.htm.

kellie-savage
Download Presentation

FP6 Thematic Priority 1: Life Sciences, Genomics, and Biotechnology for Health

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. FP6 Thematic Priority 1:Life Sciences, Genomics, and Biotechnology for Health Dr. Neil T. M. HamiltonExecutive Director

  2. Synopsis • Areas of focus in this Thematic Priority • What’s left in FP6 • Why you should be involved • How to get involved • http://www.cordis.lu/fp6/lifescihealth.htm

  3. 6th Framework Programme • 1.1.1 Life sciences, genomics and biotechnology • for health 2255 • 1.1.2. Information society technologies 3625 • 1.1.3. Nanotechnologies and nano-sciences, knowledge- • based multifunctional materials & processes 1300 • 1.1.4. Aeronautics and space 1075 • 1.1.5. Food quality and safety 685 • 1.1.6. Sustainable development, global change • and ecosystems 2120 • 1.1.7. Citizens and governance in a • knowledge-based society 225 • Budget: 3984 Billion Euros……..

  4. Thematic Priority 1: Life Sciences, Genomics and Biotechnology for Health 1.1 Advanced genomics and its application for health (€ 1100 M) • 1.1.a Fundamental knowledge and basic tools for • functional genomics in all organisms • 1.1.b Applications of knowledge and technologies in the field of genomics and biotechnology for health (€ 1155 M) 1.2 Combating major diseases • 1.2.a Application oriented genomic approaches to • medical knowledge and technologies • 1.2.b Combating cancer • 1.2.c Confronting the major communicable • diseases linked to poverty 755 M 400 M

  5. 1.1.a. Fundamental knowledge and basic tools for functional genomics in all organisms Gene expression and proteomics Structural genomics Comparative genomics and population genetics Bioinformatics Multidisciplinary functional genomics approaches to basic biological processes 110001ATC1010010101010011011AUG01101010010101101010101010TTC110101001001000CCG

  6. 1.1.b. Applications of knowledge and technologies in genomics and biotechnology for health Development of new, safer and more effective drugs including pharmacogenomics approaches Development of new diagnostics Development of new in-vitro tests to replace animal experimentation Development and testing of new preventive and therapeutic tools, such as somatic gene and cell therapies (in particular stem cell therapies, for example those on neurological and neuromuscular disorders) and immunotherapies Innovative research in post-genomics, which has high potential for application

  7. Thematic Priority 1: Life Sciences, Genomics and Biotechnology for Health Combating major diseases (1155 M € ) Medical knowledge & technologies Cancer Poverty-related diseases

  8. 1.2. Aplication-oriented genomic approaches to medical knowledge and technologies Combating cardiovascular diseases, diabetes, and rare diseases Combating resistance to antibiotics and other drugs Studying the brain and combating diseases of the nervous system Studying human development and the ageing process

  9. 1.2.b. Combating cancer A BROADER APPROACH: The focus not limited to genomics and basic research Patient-oriented strategies from prevention to diagnosis and treatment • establishing facilities for the exploitation of research on cancer in Europe; development of evidence based guidelines for good clinical practice and improved public health strategies • supporting translational research aimed at bringing basic knowledge through to applications in clinical practice and public health • supporting clinical research (clinical trials)

  10. 1.2.c. Confronting the major communicable diseases linked to poverty A BROADER APPROACH: The focus not limited to genomics and basic research • AIDS, malaria and tuberculosis • Developing promising candidate interventions (vaccines, therapies and HIV microbiocides) - molecular research, pre-clinical testing and proof of principle • Establishing a clinical trial programme for these diseases to improve coherence and complementarity - special target = interventions for use in developing countries • Establishing an AIDS Therapy Trials Network in Europe.

  11. A Pioneer New Instrumenton Structural Genomics: SPINE Structural Proteomics inEurope Objective: to develop high throughput technologies to solve 300-500 protein structures relevant to human health From production to structure analysis Duration: 3-year programme Participants: 20 partners from 7 countries EU contribution: 13.7 million € www.spineurope.org

  12. A Pioneer New Instrumenton Mouse Phenotyping: European Union Mouse Genetics Research for Public Health and Industrial Applications Objective: standardising and testing phenotyping protocols in mice Duration: 3-year programme Participants: 17 partners from 8 countries EU contribution: 12.3 million € www.eumorphia.org

  13. A Pioneer New Instrumenton Population genetics: Genome-wide analyses of European twin and population cohorts to identify genes predisposing to common diseases Objective: To harness the unique features of twin cohorts for large scale studies of environmental & genetic factors underlying complex diseases Duration: 4-year programme Participants: Originally 10 partners from 7 countries, now 13 partners from 9 countries EU contribution: 13.7 million € http://www.genomeutwin.org/

  14. What is left in FP6 ? • 555 million Euros in IST research funding; • 2005 / 06 Work Programme; • 4th (and Final) Call for Proposals; • 9th November deadline • Significant opportunities for international collaboration / co-operation

  15. 4th Call Work Programme • Final Call for Proposals in FP6 • 9th November deadline • 555 million Euros • Many but very specific areas: read the Work Programme!

  16. 4th Call Work Programme • Specific Support Action: • LSH-2005-3-2: Stimulating international co-operation: Promotion and facilitation of international co-operation in areas relevant to the objectives of this priority. Particular emphasis will be on activities involving countries having S&T co-operation agreements with the EU. Actions should aim at networking scientists for stimulating the creation of research consortia and the identification of priorities of common interest in areas supported by the Theme.

  17. Why get involved? • The Research World is changing • Europe is (trying to) take on the USA • Australia has acknowledged strengths • Students, funding, engagement….. • You need to think about, and prepare for, participation in future: FP7

  18. The European Research System • Total research spend is 1.8% of GDP • “European” and intergovernmental investment in R&D: 17% of total • European Commission (FPs) investment is on 5% of total • Member state investment DOMINATES

  19. FP6 Instruments • Specific Targeted Research Projects • Support research & demonstration activities • 3+ participants • 300k – 4 million Euros, usually 50% of costs • Integrated Projects • objective-driven research to generate new knowledge • 5 – 25 participants, with SMEs • 2 million – 20 million Euros, 50%+ of costs

  20. FP6 Instruments (cont) • Networks of Excellence • Joint Programme of Activities: • Integrating activities: sharing facilities, IP, planning • Jointly executed research • Activities for spreading excellence: training, communication, innovation, networking • Management • 15-50 participants • 3 million – 30 million Euros, up to 100% of costs

  21. FP6 Instruments (cont) • Specific Support Actions • Support implementation of FP, prepare for future Community research • 1+ participant • 100k – 3 million Euros, 100% of costs • Co-ordination Actions • Promote and support networking, joint initiatives, training, exchange, expert groups • 1+ participants • 100k – 3 million Euros, 100% of costs

  22. How to get Involved • 4th Call • Very specific topics: read the Work Programme • Join a consortium, talk to colleagues, NCPs • Specific Support Actions: all areas • “Actions should aim at networking scientists for stimulating the creation of research consortia, and the identification of priorities of common interest”

  23. Australian support for Collaboration • NH&MRC European Union Health Research Collaboration Fund • International Science Linkages (DEST) • ARC • Academies • European embassies • Many other opportunities • Remember: we already spend ~$50 million!

  24. 7th Framework Programme

  25. COST Actions – what is supported • Science management meetings • Scientific workshops and seminars • Short Term Scientific Missions • Training Schools and Research Conferences • Evaluations and Studies • Dissemination • http://cost.cordis.lu/src/home.cfm

  26. FEAST • Neil.Hamilton@anu.edu.au • 02 6125 7690 • www.feast.org • www.cordis.lu • www.europa.eu.int • http://cost.cordis.lu/

More Related